REFERENCES
- Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS. 2001;15:1369–1377.
- Mellors JW, Rinaldo CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Sci-ence. 1996;272:1167–1170.
- Mellors JW, Munoz A, Giorigi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946–954.
- O'Brien WA, Hartigan PM, Daar ES, et al. Changes in plasma HIV-1 RNA and CD+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med. 1996;334:426–454.
- Sabin CA, Fisher M, Churchill D, et al. Long-term follow-up of antiretroviral-naïve HIV-positive patients treated with nevirapine. JAIDS. 200126: 460–465.
- Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. JAMA. 1998;279:930–937.
- de Jong MD, Vella S, Carr A, et al. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppres-sion of viral replication. J Infect Dis. 1997;175:966–970.
- Floridia M, Bucciardini R, Ricciardulli D, et al. A random-ized double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse tran-scriptase HIV inhibitor, in antiretroviral-naïve patients with advanced disease. JAIDS. 1999;20:11–19.
- Wit FW. Dutch HIV-treating physicians. Experience with nevirapine in previously treated HIV-1 infected individuals. Antivir Ther. 2000;5:257–266.
- Raffi F, Reliquet V, Ferre V, et al. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naïve HIV-1 infected adults. Antivir Ther. 2000;5:267–272.
- Manfredi R. Chiodo F. First-line nevirapine in combination with nucleoside analogues compared with nevirapine added to a salvage HAART. Infection. 2000;28:167–170.
- Raboud J, Montaner JSG, Rae S, et al. Patients with higher base line pVL are less likely to have a virologic response in a meta-analysis of two trials of ZDV/ddl vs ZDV/ddl/NVP. In: Program and abstracts of the CII World Conference on AIDS; June 28—July 3, 1998; Geneva, Switzerland. Abstract 12361.